How to buy Eli Lilly stock in Canada

Eli Lilly is a drug manufacturers - general business based in the US. Eli Lilly shares (LLY) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $734.57 , which is a decrease of 10.81% over the previous week. Eli Lilly employs 47,000 staff and has a trailing 12-month revenue of around $49 billion.

Our top picks for where to buy Eli Lilly and Company stock

Buy Eli Lilly and Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Eli Lilly stock price (NYSE: LLY)

Use our graph to track the performance of LLY stocks over time.

Eli Lilly stocks at a glance

• Key figures

Information last updated 2025-05-09.

Latest market close	$734.57
52-week range	$677.09 - $969.25
50-day moving average more info button	$819.89
200-day moving average more info button	$840.77
Wall St. target price	$978.82
PE ratio more info button	59.8672
Dividend yield more info button	$5.4 (0.82%)
Earnings per share (TTM) more info button	$12.27

Is it a good time to buy Eli Lilly stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Eli Lilly stock undervalued or overvalued?

Valuing Eli Lilly stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly's P/E ratio

Eli Lilly's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 60x. In other words, Eli Lilly shares trade at around 60x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Eli Lilly's PEG ratio

Eli Lilly's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1571. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Eli Lilly's EBITDA

Eli Lilly's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $22 billion.

The EBITDA is a measure of a Eli Lilly's overall financial performance and is widely used to measure a its profitability.

Eli Lilly financials

Revenue TTM	$49 billion
Operating margin TTM	42.49%
Gross profit TTM	$40 billion
Return on assets TTM	16.45%
Return on equity TTM	77.28%
Profit margin	22.67%
Book value	$16.64
Market Capitalization more info button	$674.6 billion

TTM: trailing 12 months

Eli Lilly stock dividends

Dividend payout ratio: 40.7% of net profits

Recently Eli Lilly has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Eli Lilly's case, that would currently equate to about $5.4 per share.

While Eli Lilly's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly may be investing much of the rest of its net profits in future growth.

Eli Lilly's most recent dividend payout was on 9 March 2025. The latest dividend was paid out to all shareholders who bought their stocks by 15 May 2025 (the "ex-dividend date").

Have Eli Lilly's stocks ever split?

Eli Lilly's stocks were split on a 2:1 basis on 15 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Eli Lilly stocks, which in turn could have impacted Eli Lilly's stock price.

Eli Lilly stock price volatility

Over the last 12 months, Eli Lilly's stocks have ranged in value from as little as $677.0912 up to $969.2515. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly's is 0.472. This would suggest that Eli Lilly's stocks are less volatile than average (for this exchange).

Eli Lilly overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Eli Lilly is owned by insiders or institutions?
Currently 0.162% of Eli Lilly stocks are held by insiders and 83.51% by institutions. How many people work for Eli Lilly?
Latest data suggests 47,000 work at Eli Lilly. When does the fiscal year end for Eli Lilly?
Eli Lilly's fiscal year ends in December. Where is Eli Lilly based?
Eli Lilly's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285 What is Eli Lilly's ISIN number?
Eli Lilly's international securities identification number is: US5324571083 What is Eli Lilly's CUSIP number?
Eli Lilly's Committee on Uniform Securities Identification Procedures number is: 532457108

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.